UnitedHealthcareMedium ImpactCoverage
Maryland Medicaid to cover cell and gene therapy for sickle cell disease
Published June 3, 2026Effective January 1, 2026
AI Summary
Starting January 1, 2026, Maryland Medicaid now covers FDA-approved cell and gene therapies (Casgevy and Lyfgenia) for sickle cell disease through the Cell and Gene Therapy Access Model. Coverage includes evaluation, apheresis, infusion, recovery and long-term follow-up at authorized treatment centers.
Action Required
Immediately: Providers treating Maryland Medicaid members with sickle cell disease should discuss cell and gene therapy options and refer appropriate patients for evaluation at authorized treatment centers. Billing team should verify coverage for Casgevy and Lyfgenia therapies through the CGT Access Model for Maryland Medicaid claims.
Plan Types
Medicaid
States
MD
Specialties
hematology, oncology, family-medicine, internal-medicine, pediatrics